Several national patient organizations representing the Alpha-1 antitipsin, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre, hemophilia, platelet disorders, primary immunodeficiency diseases and other rare disease communities have formed a group to address the unique needs of users of “plasma protein therapies” (plasma derived and recombinant therapies). To address the uniqueness of PUC’s membership, the group developed health care reform general principles for rare diseases. HFA is a member of the PUC and fully supports the elements outlined in Principles for Health Care Reform and the Rare Disease Community.

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.